Faron Pharmaceuticals (LSE:FARN), the Finnish clinical-stage drug developer, said on 4 November 2026 that five abstracts on its lead antibody bexmarilimab had been accepted for poster presentation at the 68th American Society of Hematology annual meeting, to be held in New Orleans from 12 to 15 December 2026. The abstracts include overall survival results from its BEXMAB study in higher-risk myelodysplastic syndrome, a form of blood cancer.

Company Overview

Faron is based in Turku, Finland, and is listed on both AIM and Nasdaq First North in Helsinki. Its lead asset, bexmarilimab, is a humanised antibody that targets Clever-1, a receptor found on certain immune cells. The company is studying it in blood cancers and solid tumours, with its main focus on higher-risk myelodysplastic syndrome, known as HR-MDS.

Myelodysplastic syndromes are a group of blood disorders in which the bone marrow does not produce healthy blood cells. Higher-risk forms are the area in which LSE:FARN has concentrated its development work with bexmarilimab.

Azacitidine is a standard treatment used in HR-MDS, and bexmarilimab is being studied in combination with it. Clever-1 is a receptor on certain immune cells, and the company's approach is to target it with the aim of influencing how those cells behave within the tumour environment.

Latest Developments

Data due to be presented at ASH show that, in 20 evaluable frontline HR-MDS patients treated with bexmarilimab and azacitidine, the overall response rate was 85% and the complete remission rate was 45%, with a median duration of complete remission of 16.1 months. Median overall survival across that cohort was 12.1 months, and 8.8 months in patients with biallelic TP53 mutations.

The American Society of Hematology annual meeting is one of the main scientific gatherings in blood disorders, and poster presentations allow companies to present data to specialists in the field. The five accepted abstracts cover survival results, trial design and other aspects of the bexmarilimab programme.

In 33 evaluable relapsed or refractory patients whose disease had progressed after hypomethylating agents, the response rate was 64% and median overall survival was 11.2 months. Faron said the safety profile appeared comparable to azacitidine alone.

Another abstract describes the design of BEXERA, a randomised, double-blind, placebo-controlled phase 2b trial in about 90 previously untreated HR-MDS patients at about 35 sites. Patients will receive one of two doses of bexmarilimab or placebo, each with azacitidine. Faron has said the trial is intended to select a dose for phase 3 and support future registration filings, and it announced a collaboration with Parexel in April 2026 to support it.

A randomised, double-blind trial compares a treatment with a placebo without either the patients or the investigators knowing who receives which, which is designed to give a clear comparison of the effect of the treatment being studied.

Parexel is a provider of clinical trial services, and the collaboration announced in April 2026 is intended to support the conduct of BEXERA. A phase 2b trial of this kind is designed to help select the dose that would be taken forward into a phase 3 study.

Financial Picture

Faron's half-year report, published on 26 August 2026, showed cash of €32.0m at 30 June 2026, up from €13.5m a year earlier, after a rights issue completed in April 2026 that raised €40.1m gross. The loss for the first half was €8.5m, compared with €19.3m a year earlier, and R&D spending was €7.6m.

A rights issue gives existing shareholders the opportunity to subscribe for new shares in proportion to their holdings. The April 2026 issue raised €40.1m gross and contributed to cash rising to €32.0m at 30 June 2026 from €13.5m a year earlier. The reduction in the first-half loss to €8.5m from €19.3m accompanies R&D spending of €7.6m.

Borrowings were about €17.8m. In August, special rights were exercised for about €1.6m, linked to scheduled bond amortisation. The company does not pay a Dividend and does not give a short-term outlook.

Sector and index Context

Faron is an oncology-focused drug developer within the healthcare segment of the FTSE AIM All Share Index. Companies of this kind are followed closely around trial readouts and scientific meetings, as these events provide data on how their treatments are performing.

Meetings such as ASH give investors and clinicians a chance to compare the data from different programmes, including those that report overall survival in similar patient groups.

A separate meta-analysis abstract, covering 61 cohorts and 5,034 patients, found pooled median overall survival of 6.68 months in arms enrolling only higher-risk MDS patients, which provides context for the survival figures reported by LSE:FARN.

Factors to Monitor

The data presented so far come from relatively small, single-arm studies, and the randomised BEXERA trial is designed to provide a more rigorous comparison. The company's cash position and borrowings, and the progress of its development programme, will determine the timing of its next steps. Regulatory requirements and the treatment landscape in MDS are further considerations as the programme advances.

What to Watch Next

The ASH posters in December, the start of patient enrolment in BEXERA, which was planned for the second half of 2026, and updates from investigator-initiated trials in solid tumours and acute myeloid leukaemia are the main near-term events for LSE:FARN. Market Participants will also follow its cash use and any financing announcements.